Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells

Hiľovská,Lucia; Jendželovský,Rastislav; Jendželovská,Zuzana; Kovaľ,Ján; Fedoročko,Peter

doi:10.3892/ijo.2015.3116

Downregulation of BCRP and anti-apoptotic proteins by proadifen (SKF-525A) is responsible for the enhanced mitoxantrone accumulation and toxicity in mitoxantrone-resistant human promyelocytic leukemia cells

Authors:
- Lucia Hiľovská
- Rastislav Jendželovský
- Zuzana Jendželovská
- Ján Kovaľ
- Peter Fedoročko
View Affiliations

Affiliations: Institute of Biology and Ecology, Department of Cellular Biology, Pavol Jozef Šafárik University in Košice, SK-040 01 Košice, Slovak Republic
Published online on: August 6, 2015 https://doi.org/10.3892/ijo.2015.3116
Pages: 1572-1584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multidrug resistance caused by the overexpression of ABC transporter proteins in cancer cells remains a major obstacle limiting chemotherapy efficacy. Drugs inhibiting these transporters have been shown to increase the anti-proliferative properties of chemotherapeutics. As we previously described, proadifen, a P450 monooxygenase inhibitor, might also be able to inhibit some ABC transporters, including breast cancer resistance protein (BCRP). Because mitoxantrone (MTX) is a strong BCRP substrate and is often used in the treatment of leukemia, we investigated the effect of 24 h proadifen pre-treatment on the cytotoxicity of MTX in leukemic cell lines that are sensitive to MTX (HL-60) and MTX-resistant ABCG2-overexpressing subclone (cBCRP). We show for the first time that proadifen is able to enhance the cytotoxic properties of MTX in cBCRP cells, particularly through the inhibition of BCRP expression and activity. This proadifen-MTX synergism was also mediated by the inhibition of various cellular proteins engaged in apoptosis, including Mc-1, Bcl-xL, survivin and activation of procaspase-3. Proadifen also decreased the expression of γH2AX, which is involved in the recruitment of reparation proteins. Moreover, the inhibition of DNA damage repair proteins Ku86 and B23 after proadifen treatment indicate a possible role of proadifen in DNA repair blockage, thus suppressing the reparation rate of MTX-induced DSBs.

View Figures

View References

1	Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD and Burger AM: Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer. 102:815–826. 2010. View Article : Google Scholar : PubMed/NCBI
2	Hu C, Li H, Li J, Zhu Z, Yin S, Hao X, Yao M, Zheng S and Gu J: Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis. 29:2289–2297. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hu L, McArthur C and Jaffe RB: Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 102:1276–1283. 2010. View Article : Google Scholar : PubMed/NCBI
4	Salcido CD, Larochelle A, Taylor BJ, Dunbar CE and Varticovski L: Molecular characterisation of side population cells with cancer stem cell-like characteristics in small-cell lung cancer. Br J Cancer. 102:1636–1644. 2010. View Article : Google Scholar : PubMed/NCBI
5	Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y, Huang Q, Jiang L, Huang W, Cheng W, et al: Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem. 340:265–273. 2010. View Article : Google Scholar : PubMed/NCBI
6	Natarajan K, Xie Y, Baer MR and Ross DD: Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
7	Diah SK, Smitherman PK, Aldridge J, Volk EL, Schneider E, Townsend AJ and Morrow CS: Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: Evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 61:5461–5467. 2001.PubMed/NCBI
8	Jendzelovský R, Mikes J, Koval' J, Soucek K, Procházková J, Kello M, Sacková V, Hofmanová J, Kozubík A and Fedorocko P: Drug efflux transporters, MRP1 and BCRP, affect the outcome of hypericin-mediated photodynamic therapy in HT-29 adenocarcinoma cells. Photochem Photobiol Sci. 8:1716–1723. 2009. View Article : Google Scholar : PubMed/NCBI
9	Jendželovský R, Koval J, Mikeš J, Papčová Z, Plšíková J and Fedoročko P: Inhibition of GSK-3β reverses the pro-apoptotic effect of proadifen (SKF-525A) in HT-29 colon adenocarcinoma cells. Toxicol In Vitro. 26:775–782. 2012. View Article : Google Scholar
10	Ozvegy-Laczka C, Hegedus T, Várady G, Ujhelly O, Schuetz JD, Váradi A, Kéri G, Orfi L, Német K and Sarkadi B: High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol. 65:1485–1495. 2004. View Article : Google Scholar : PubMed/NCBI
11	Kleban J, Mikes J, Szilárdiová B, Koval J, Sacková V, Solár P, Horváth V, Hofmanová J, Kozubík A and Fedorocko P: Modulation of hypericin photodynamic therapy by pretreatment with 12 various inhibitors of arachidonic acid metabolism in colon adenocarcinoma HT-29 cells. Photochem Photobiol. 83:1174–1185. 2007. View Article : Google Scholar : PubMed/NCBI
12	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
13	Jendželovská Z, Jendželovský R, Hiľovská L, Kovaľ J, Mikeš J and Fedoročko P: Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells. Toxicol In Vitro. 28:1259–1273. 2014. View Article : Google Scholar
14	Kretschy N, Teichmann M, Kopf S, Atanasov AG, Saiko P, Vonach C, Viola K, Giessrigl B, Huttary N, Raab I, et al: In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. Br J Cancer. 108:570–578. 2013. View Article : Google Scholar : PubMed/NCBI
15	Spitzmaul G, Gumilar F, Dilger JP and Bouzat C: The local anaesthetics proadifen and adiphenine inhibit nicotinic receptors by different molecular mechanisms. Br J Pharmacol. 157:804–817. 2009. View Article : Google Scholar : PubMed/NCBI
16	Hoferová Z, Soucek K, Hofmanová J, Hofer M, Chramostová K, Fedorocko P and Kozubik A: In vitro proliferation of fibrosarcoma cells depends on intact functions of lipoxygenases and cytochrome P-450-monooxygenase. Cancer Invest. 22:234–247. 2004. View Article : Google Scholar : PubMed/NCBI
17	Hofmanová J, Soucek K, Dusek L, Netíková J and Kozubík A: Inhibition of the cytochrome P-450 modulates all-trans-retinoic acid-induced differentiation and apoptosis of HL-60 cells. Cancer Detect Prev. 24:325–342. 2000.PubMed/NCBI
18	Huang YC and Han YS: Determining anti-betanodavirus compounds through a GF-1 cell-based screening platform. Antiviral Res. 105:47–53. 2014. View Article : Google Scholar : PubMed/NCBI
19	Fernández G, Villarruel MC, Bernacchi A, de Castro CR and Castro JA: Effects of repeated administration of rat 2-diethyl-aminoethyl-2-2-diphenylvalerate-HCI (SKF 525 A) on liver. Toxicology. 20:185–193. 1981. View Article : Google Scholar
20	Elahian F, Kalalinia F and Behravan J: Evaluation of indo-methacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines. Drug Chem Toxicol. 33:113–119. 2010. View Article : Google Scholar : PubMed/NCBI
21	Chu TS, Chen JS, Lopez JP, Pardo FS, Aguilera J and Ongkeko WM: Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 134:979–984. 2008. View Article : Google Scholar : PubMed/NCBI
22	Nakanishi T, Shiozawa K, Hassel BA and Ross DD: Complex interaction of BCRP/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression. Blood. 108:678–684. 2006. View Article : Google Scholar : PubMed/NCBI
23	Rosenfeldt MT, Bell LA, Long JS, O'Prey J, Nixon C, Roberts F, Dufès C and Ryan KM: E2F1 drives chemotherapeutic drug resistance via ABCG2. Oncogene. 33:4164–4172. 2014. View Article : Google Scholar
24	Breitenbuecher F, Markova B, Kasper S, Carius B, Stauder T, Böhmer FD, Masson K, Rönnstrand L, Huber C, Kindler T, et al: A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. Blood. 113:4063–4073. 2009. View Article : Google Scholar : PubMed/NCBI
25	Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et al: Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26:120–125. 2012. View Article : Google Scholar : PubMed/NCBI
26	Hermanson DL, Das SG, Li Y and Xing C: Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase IIβ downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia. Mol Pharmacol. 84:236–243. 2013. View Article : Google Scholar : PubMed/NCBI
27	Fuessel S, Herrmann J, Ning S, Kotzsch M, Kraemer K, Schmidt U, Hakenberg OW, Wirth MP and Meye A: Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxy-nucleotides and siRNA. Cancer Lett. 232:243–254. 2006. View Article : Google Scholar : PubMed/NCBI
28	Dong H, Liu G, Jiang B, Guo J, Tao G, Yiu W, Zhou J and Li G: The effects of aspirin plus cisplatin on SGC7901/CDDP cells in vitro. Biomed Rep. 2:344–348. 2014.PubMed/NCBI
29	Li G, Zhang S, Fang H, Yan B, Zhao Y, Feng L, Ma X and Ye X: Aspirin overcomes Navitoclax-resistance in hepatocellular carcinoma cells through suppression of Mcl-1. Biochem Biophys Res Commun. 434:809–814. 2013. View Article : Google Scholar : PubMed/NCBI
30	Bank A, Yu J and Zhang L: NSAIDs downregulate Bcl-X(L) and dissociate BAX and Bcl-X(L) to induce apoptosis in colon cancer cells. Nutr Cancer. 60(Suppl 1): S98–S103. 2008. View Article : Google Scholar
31	Zhang DQ, Guo Q, Zhu JH and Chen WC: Increase of cyclo-oxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer. World J Surg Oncol. 11:162013. View Article : Google Scholar
32	Paull TT, Rogakou EP, Yamazaki V, Kirchgessner CU, Gellert M and Bonner WM: A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol. 10:886–895. 2000. View Article : Google Scholar : PubMed/NCBI
33	Kalra RS and Bapat SA: Enhanced levels of double-strand DNA break repair proteins protect ovarian cancer cells against genotoxic stress-induced apoptosis. J Ovarian Res. 6:662013. View Article : Google Scholar : PubMed/NCBI
34	Koike A, Nishikawa H, Wu W, Okada Y, Venkitaraman AR and Ohta T: Recruitment of phosphorylated NPM1 to sites of DNA damage through RNF8-dependent ubiquitin conjugates. Cancer Res. 70:6746–6756. 2010. View Article : Google Scholar : PubMed/NCBI